eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

sanofi-aventis

1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Patient Information Leaflet last updated on the eMC: 23/02/2011
PIL Xatral XL

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 23/02/2011 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change of contra-indications
  • Change to instructions about overdose
  • Change to side-effects
  • Change to drug interactions
  • Change to information about driving or using machinery
Updated on 23/02/2009 and displayed until 23/02/2011
Reasons for adding or updating:
  • Change due to user-testing of patient information
Updated on 15/02/2008 and displayed until 23/02/2009
Reasons for adding or updating:
  • Change due to user-testing of patient information
  • Change to date of revision
  • Change to information about drinking alcohol
  • Change to information about driving or using machinery
  • Change to storage instructions
  • Change to Further Information section
Updated on 18/11/2005 and displayed until 15/02/2008
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 11/05/2004 and displayed until 18/11/2005
Reasons for adding or updating:
  • Change to, or new, use for medicine
  • Change to how to administer the medicine
Updated on 18/10/2002 and displayed until 11/05/2004
Reasons for adding or updating:
  • New PIL for eMC ie a PIL for an existing product but new to the eMC

Active Ingredients/Generics

 
   alfuzosin hydrochloride